CureMD's Oncology EHR — First To Include Real-Time Oncology Clinical Decision Support

CureMD’s Oncology EHR, a specialty product of CureMD’s Smart Cloud EHR solutions, now includes real-time oncology clinical decision support through eviti, Inc., a national leader in oncology clinical information.
New York, NY (PRWEB) - CureMD’s Oncology EHR, a specialty product of CureMD’s Smart Cloud EHR solutions, now includes real-time oncology clinical decision support through eviti, Inc., a national leader in oncology clinical information.
Physicians using CureMD’s Oncology EHR will now have ready access at the point of care to eviti, Inc.’s clinical decision support library, enabling them to have the latest treatment protocols and clinical trial data available at their fingertips—providing patients, caregivers and referring physicians high quality treatment options for discussion and selection.
Kamal Hashmat, CEO of CureMD said, “We remain committed to enhancing our Smart Cloud EHR for Oncologists and have joined with eviti, Inc. in their mission to give patients and their care deliverers the best fighting chance.” He continued, “I can’t think of a better use for their real-time data and our common, web-based technology platform.”
Located in Philadelphia, eviti, Inc. supports physician decision-making with the most comprehensive and unbiased single information source of available cancer treatments for all cancer types. Their robust library— with 1,400+ evidence-based regimens and 10,000+ cancer clinical trials—is meticulously compiled from data that originates from internationally recognized governmental and industrial sources; and is maintained by: oncology professionals, a world-class medical advisory board and medical informatics professionals.
eviti, Inc. CEO, Eduardo Beruff, said, “We are pleased to be working with CureMD to make clinical decision support available through a system with which oncologists are familiar. Having easy access to such a robust clinical library will assist oncology specialists in comparing high quality treatment plans based on outcomes, costs and efficiency—providing better tools for selecting the most appropriate treatment for each patient.”
CureMD is the first EHR to incorporate evidence-based treatment protocols from eviti, Inc. into its award-winning Smart Cloud, All-In-One, Oncology EHR.
CureMD is a New York based, award-winning network of health information management systems and services, offering certified EHR, practice management, patient portal, revenue cycle management and transcription to help accelerate adoption and Meaningful Use qualification—driving outcomes and subsidy payments to maximize value and returns.CureMD’s advanced web technology and usability facilitate quality decision making, streamline operations and ensure compliance. For more information, visit http://www.curemd.com.
eviti, Inc. is a leading health information technology and clinical decision-support company delivering solutions to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start. eviti's growing national prominence is evidenced by the 2,000+ oncology practices already registered to use the eviti platform. eviti's independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world's leading sources. eviti's treatment knowledge base and patent-pending decision support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient's insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement; reduces variability in clinical care; and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit http://www.eviti.com.
Source: PRWeb
View original release here: http://www.prweb.com/releases/2012/10/prweb9966746.htm